First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

ConclusionsOleclumab  ± durvalumab had a manageable safety profile, with pharmacodynamic activity reflecting oleclumab’s mechanism of action. Evidence of antitumor activity was observed in tumor types that are generally immunotherapy resistant.Clinical trial registrationClinicaltrials.gov, NCT02503774; date of registration, July 17, 2015.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research